Your browser doesn't support javascript.
loading
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.
Gianni, L; Huang, C S; Egle, D; Bermejo, B; Zamagni, C; Thill, M; Anton, A; Zambelli, S; Bianchini, G; Russo, S; Ciruelos, E M; Greil, R; Semiglazov, V; Colleoni, M; Kelly, C; Mariani, G; Del Mastro, L; Maffeis, I; Valagussa, P; Viale, G.
Affiliation
  • Gianni L; Fondazione Michelangelo, Milan, Italy. Electronic address: luca.gianni@fondazionemichelangelo.org.
  • Huang CS; National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, Taiwan.
  • Egle D; Department of Gynecology, Brust Gesundheit Zentrum Tirol, Medical University Innsbruck, Innsbruck, Austria.
  • Bermejo B; Hospital Clinico Universitario, Valencia, Spain.
  • Zamagni C; Addarii Medical Oncology IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Thill M; Agaplesion Markus Krankenhaus, Frankfurt am Main, Germany.
  • Anton A; Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Zambelli S; San Raffaele Hospital, Milano, Italy.
  • Bianchini G; San Raffaele Hospital, Milano, Italy.
  • Russo S; Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
  • Ciruelos EM; Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Greil R; 3rd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria; Salzburg Cancer Research Institute-CCCIT, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria.
  • Semiglazov V; NN Petrov Research Institute of Oncology, St. Petersburg, Russia.
  • Colleoni M; IEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.
  • Kelly C; Trinity St James's Cancer Institute, St James's Hospital, Dublin, Ireland.
  • Mariani G; Istituto Nazionale Tumori, Milan, Italy.
  • Del Mastro L; IRCCS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Dipartimento di Medicina Interna e Specialità Mediche (Di.M.I.), Genoa, Italy.
  • Maffeis I; Fondazione Michelangelo, Milan, Italy.
  • Valagussa P; Fondazione Michelangelo, Milan, Italy.
  • Viale G; IEO, Istituto Europeo di Oncologia, IRCCS, Milan, Italy; University of Milan, Milan, Italy.
Ann Oncol ; 33(5): 534-543, 2022 05.
Article de En | MEDLINE | ID: mdl-35182721
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Traitement néoadjuvant / Tumeurs du sein triple-négatives Type d'étude: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2022 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Traitement néoadjuvant / Tumeurs du sein triple-négatives Type d'étude: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Female / Humans Langue: En Journal: Ann Oncol Sujet du journal: NEOPLASIAS Année: 2022 Type de document: Article